


This is a paid press release. Contact the press release distributor directly with any inquiries.

Mount Sinai Medical Center Installs Koning Vera Breast CT System, Expanding Access to Advanced Breast Imaging in Florida

PR Newswire
September 4, 2025 - 2 min read

MIAMI, Sept. 4, 2025 /PRNewswire/ -- Koning Health, a leader in advanced breast imaging technology, announced the installation of the Koning Vera Breast CT System at Mount Sinai Medical Center in Miami Beach, one of **America's 100 Best Hospitals™** by Healthgrades™ for 2024 & 2025.



Installation of Koning Vera at Mount Sinai in Miami

Mount Sinai's Koning Vera Breast CT is the first dedicated breast CT installed into a comprehensive breast imaging center in Florida. Its true three-dimensional imaging offers physicians unprecedented clarity for visualizing breast tissue while providing patients with a fast, non-invasive exam.

The Koning Vera will be used both commercially for patient care and to support clinical data collection initiatives at Mount Sinai, further strengthening the institution's ability to evaluate cutting-edge technologies that improve breast health outcomes.

"This installation represents a significant step forward in breast imaging innovation for Florida," said David Georges, President of Koning US. "Mount Sinai's adoption of the Koning Vera not only offers patients with a more comfortable, compression-free breast exam experience but also advances clinical research that will help shape the future of breast cancer detection and care."

"Mount Sinai has a long-standing commitment to advancing cancer care through innovation and research," said Gino R. Santoro, President and CEO of Mount Sinai Medical Center. "As we prepare to open the Brannan Comprehensive Cancer Center, the addition of Koning Vera to our imaging program reflects that commitment—expanding access to cutting-edge technology that enhances patient comfort today while laying the foundation for tomorrow's breakthroughs in breast cancer detection and treatment."

With breast cancer remaining one of the most prevalent cancers among women, the expansion of advanced imaging technologies like the Koning Vera across leading institutions ensures that more patients have access to accurate, efficient, and patient-centered diagnostic tools.

About Koning: Koning is a global health technology company advancing innovation in breast imaging with its patented Koning Vera Breast CT (KBCT). Koning's vision is to transform medical imaging through advanced computed tomography technology, providing clinicians with new ways to visualize and evaluate breast tissue. The Koning Vera is designed to offer true 3D imaging and a patient-centered exam experience, supporting both clinical practice and ongoing research in breast health.

For more information, please visit www.koninghealth.com or email info@koningcorporation.com.

Story Continues

Terms and Privacy Policy Privacy Dashboard

Quote Lookup

U.S. markets closed

US	Europe	Asia	Cryptocurrencies	Rate
S&P 500	Dow 30	Nikkei		
6,838.47	48,800.83	25,548.67		
+12.15	+10.25	+21.47		
Bitcoin	Ethereum	Cardano		
94,111	3,421.12	0.43		
+1,111.11	+10.10	+0.01		
Gold	Oil			
2,644.70	81.30	4,976.30		
+12.34	+0.12	+1.23		
+1.18%	+1.87%	+1.47%		

Trending Tickers

ETC-USO	64.26	60
Bitcoin USD	+1.18	+1.87%
NVDA	90.76	
NVIDIA Corporat...	+4.80	+5.28%
SNOW	284.58	
Snowflake Corporat...	+3.73	+1.32%
NIJ	418.68	
Micro Technolo...	+2.21	+0.53%
QQQ	408.92	
Invesco QQQ Trust	+1.31	+0.32%

Portfolio

Sign in to access your portfolio

Sign In

Top gainers

EMAT	9.30	
Evolution Metall...	+1.28	+13.90%
TRV	45.27	
Ti Pointe Home...	+4.80	+10.20%
SPWR	12.28	
SPWR Automatio...	+1.73	+16.57%
NIJ	68.72	
Micro Technolo...	+2.21	+3.21%
COIN	164.22	
Coinbase Global	+10.21	+6.25%

Top losers

HOV	35.88	
Hov Medicine, Inc.	-4.20	-11.70%
BRAM	68.80	
Bright Horizons	-4.81	-6.99%

GlobalData

QT Imaging and Olea Medical collaborate on cloud-based breast analytics



The solution offers secure network access for multi-institution collaboration - Hospital Management

Sakong Debbarma
January 26, 2025 - 2 min read

In this article

QTH -1.91%

QT Imaging Holdings has announced a new collaboration with Olea Medical to advance cloud-based breast imaging analytics.

The partnership aims to integrate Olea Medical's advanced visualisation, quantitative analytics and AI-ready imaging technologies into QT Imaging's Cloud SaaS Platform, supporting research workflows, quantitative imaging analysis, and clinical interpretation.

It builds on QT Imaging's enterprise PACS and cloud infrastructure, delivered via the InteleShare platform, which underpins the company's clinical and research deployments.

By combining the capabilities, the partnership enables secure delivery of QT Imaging Breast Acoustic CT studies with advanced quantitative analysis, high-performance visualisation, and multimodality integration.

As part of the collaboration, QT Imaging data will be enabled for clinical interpretation within the company's infrastructure by incorporating Olea Medical's analytics technologies and validated visualisation.

The integrated solution enables scalable multimodality breast imaging by combining digital breast tomosynthesis (DBT), mammography, magnetic resonance (MR) imaging and ultrasound with QT Imaging studies across the entire breast care pathway.

It offers secure network-enabled access to facilitate collaboration between multiple institutions, centralised research workflows, and uniform support for clinical trials.

This partnership aligns with QT Imaging's plans to increase the adoption of its Breast Acoustic CT technology and facilitate future AI and machine learning analytics via its cloud infrastructure.

Through the agreement, the company will offer the QT Imaging Olea Vision software, a configurable 3D and 4D digital imaging and communications in medicine (DICOM) viewer.

This software enables user-defined hanging protocols, intuitive navigation through DICOM series, advanced 3D data visualisation and image manipulation, and includes subtraction tools for improved diagnostic assessment.

QT Imaging CEO Dr Reluca Dinu said: "Our collaboration with Olea Medical strengthens the clinical visualisation and analytical capabilities of QT Imaging's cloud platform.

"Together with the enterprise delivery infrastructure we are putting in place, this collaboration supports our mission to deliver advanced, quantitative breast imaging at scale for both research and clinical care."

Recently, QT Imaging signed an exclusive distribution agreement with Al Naghi Medical (NMC) for its QTI Breast Acoustic CT scanners and Cloud Platform in the UAE.


"QT Imaging and Olea Medical collaborate on cloud-based breast analytics" was originally created and published by Hospital

Story Continues

Terms and Privacy Policy Privacy Dashboard

GlobalData

OncoRes Medical raises funding to advance Elora clinical development



The Elora probe generates micro-scale 3D maps of mechanical and optical properties following excision during BCS. Credit: Maria Shlyeva / Shutterstock.com - Medical Device Network - Mary Shlyeva / Shutterstock.com

Sakong Debbarma
Fri, February 15, 2025 at 6:59 AM GMT-5 - 2 min read

Australia-based OncoRes Medical has completed A\$27m(\$19.1m) private funding round to support the clinical development and regulatory advancement of its quantitative micro-elastography (QME) imaging system, Elora.

The funding round saw participation from Brandon Capital Partners' BB6 Fund, Radar Ventures, Morgans, The Table Club network, and Australian and international family offices.

Elora delivers real-time analysis of tumours, enabling surgeons to identify and excise cancerous tissue with accuracy. It is designed to enhance outcomes in breast-conserving surgery (BCS) and may cut the frequency of repeat procedures for breast cancer patients.

It also enables detailed, real-time intraoperative tumour cavity assessment.

The company has initiated a clinical trial involving six hospitals located in Western Australia and Victoria. The study aims to recruit over 110 breast cancer patients and represents the first interventional use of the Elora device.

Elora received the US Food and Drug Administration (FDA) breakthrough device designation in 2020, which is designed to accelerate the development and approval of devices addressing life-threatening conditions, supporting expedited approval and reimbursement upon clearance.

The Elora probe generates micro-scale 3D maps of mechanical and optical properties following excision during BCS.

These imaging maps enable surgeons to detect residual cancerous tissue, allowing for more thorough removal of microscopic or non-palpable tumours left in the breast cavity.

As part of its initiative toward regulatory approval and commercialisation in the US market, OncoRes has appointed Renee Ryan as a new board member.

OncoRes Medical CEO Dr Katharine Giles said: "This injection of capital represents a strong endorsement of our technology and its potential to positively impact so many lives.

"The funding will be immediately deployed to support our Australian clinical trial, together with product development, regulatory milestones and manufacturing for our US pivotal trial.

"We will also expand the team and progress proof-of-concept work for this technology in other cancer types, including prostate cancer, which is deeply exciting."


"OncoRes Medical raises funding to advance Elora clinical development" was originally created and published by Medical Device Network, a GlobalData owned brand.

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Terms and Privacy Policy Privacy Dashboard

GlobalData

FDA clears Spectrum Dynamics' Veritas.AI platform



Medical Device Network - Hufjffjff vs Shutterstock

Ross Law
January 30, 2025 - 2 min read

Spectrum Dynamics Medical has gained US Food and Drug Administration (FDA) clearance for the Veritas.AI Noise Reduction platform, setting the company up to advance the performance capabilities of its VERITON-CT SPECT/CT nuclear imaging system.

Veritas.AI uses a deep learning convolutional neural network (CNN) that is designed to reduce image noise while preserving spatial resolution and quantitative accuracy. According to Spectrum Dynamics, the platform has been clinically validated for applications and tracers including bone imaging and Lu-177 theranostics, a treatment for prostate cancer patients, and will reduce VERITON-CT scan time by up to 50%.

The platform is also expected to improve VERITON-CT's image quality in low-count and high-noise conditions within what Spectrum describes as some of nuclear medicine's "most demanding" imaging scenarios.

Spectrum Dynamics' CEO Tomer Gabay commented: "Veritas.AI strengthens our commitment to precision imaging by delivering clearer images, greater clinical confidence, and more efficient workflows, while helping hospitals prepare for the rapid growth of theranostics and quantitative SPECT/CT."

Recent developments in nuclear imaging

At the recent JP Morgan Healthcare Conference, GE HealthCare announced plans to scale its nuclear imaging portfolio. According to GlobalData analysis, the imaging giant holds an estimated 34% share of the positron emission tomography (PET) and single-photon emission computed tomography (SPECT) equipment market.

Commenting on GE HealthCare's plans to scale, GlobalData analysts note that management's discussion of PET Omni – the company's main PET-CT system that was introduced in 2022 – and other pipeline products fit a strategy of "staying ahead in equipment" but also using its installed base to support "recurring, procedure-linked revenue".